title: [Protective properties of candidate genetically engineered vaccines against avian influenza viruses constructed on the basis of recombinant adenoviral vectors].
abstract: OBJECTIVE
  To design and study the properties of candidate vaccines against avian influenza based on recombinant adenoviral vectors expressing H5 hemagglutinin.
  
  
  METHODS
  Recombinant adenoviral vectors were constructed as described in "Stratagene" (Ad Easy Adenoviral Vector System). For immunization of animals, recombinant candidate vaccines were administered intranasally twice. Titer of hemagglutinating antibodies were measured by hemaglutination inhibition assay.
  
  
  RESULTS
  It was demonstrated that administration of vaccines to animals completely protects them from a lethal dose challenge with H5N2 influenza virus. Protective effect of vaccines remained for 6 months after immunization. Additionally, highly effective cross-protection of the immunized animals against heterologous strain of H5 influenza virus was demonstrated.
  
  
  CONCLUSIONS
  Obtained results show good prospects for usage of recombinant adenoviral vectors as a basis for development of new generation effective vaccines against influenza.
authors: E S
authors: ES
authors: Sedova
authors: M M
authors: MM
authors: Shmarov
authors: I L
authors: IL
authors: Tutykhina
authors: Iu A
authors: IuA
authors: Barykova
authors: L V
authors: LV
authors: Verkhovskaia
authors: D Iu
authors: DIu
authors: Logunov
authors: B S
authors: BS
authors: Naroditskiĭ
authors: A L
authors: AL
authors: Gintsburg
mesh_terms: D000256:Adenoviridae / Q000235:genetics; D000281:Administration, Intranasal; D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D000956:Antigens, Viral / Q000276:immunology*; D003429:Cross Reactions; D004353:Drug Evaluation, Preclinical; D005260:Female; D005818:Genetic Engineering; D005822:Genetic Vectors / Q000235:genetics; D006385:Hemagglutination Inhibition Tests; D019267:Hemagglutinin Glycoproteins, Influenza Virus / Q000235:genetics / Q000276:immunology*; D006801:Humans; D007115:Immunization Schedule; D053125:Influenza A Virus, H5N2 Subtype / Q000276:immunology*; D007252:Influenza Vaccines / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology*; D007251:Influenza, Human / Q000276:immunology / Q000517:prevention & control*; D051379:Mice; D008807:Mice, Inbred BALB C; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology
chemical_list: D000914:Antibodies, Viral; D000956:Antigens, Viral; D019267:Hemagglutinin Glycoproteins, Influenza Virus; D007252:Influenza Vaccines; D014614:Vaccines, Synthetic; C109963:hemagglutinin, avian influenza A virus